Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
BriaCell Therapeutics Corp. Warrant (BCTXZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: BCTXZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -4.44% | Avg. Invested days 6 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.91 - 1.51 | Updated Date 04/29/2025 |
52 Weeks Range 0.91 - 1.51 | Updated Date 04/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp. Warrant
Company Overview
History and Background
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for advanced cancers. The company was founded to address unmet needs in cancer treatment by harnessing the power of the immune system.
Core Business Areas
- Immunotherapy Development: Developing and testing novel cancer immunotherapies, including Bria-IMTu2122, a targeted immunotherapy approach.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its immunotherapy candidates in various cancer types.
- Companion Diagnostics: Developing companion diagnostics to identify patients most likely to benefit from BriaCell's therapies.
Leadership and Structure
BriaCell Therapeutics Corp. is led by a management team with experience in oncology and biotechnology. The organizational structure includes departments focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is BriaCell's lead investigational immunotherapy for advanced breast cancer. The market share is currently negligible as it is under development. Competitors include established pharmaceutical companies offering chemotherapy and targeted therapies, such as Pfizer, Novartis, and Roche, as well as companies developing other immunotherapies, like Merck (MRK) and Bristol-Myers Squibb (BMY).
Market Dynamics
Industry Overview
The oncology market is a rapidly growing field driven by increasing cancer incidence and advancements in treatment options, including immunotherapies.
Positioning
BriaCell aims to position itself as a leader in targeted cancer immunotherapy, focusing on personalized treatment approaches.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to be in the tens of billions of dollars. BriaCell is positioned to capture a portion of this market through its targeted immunotherapy approach, particularly if Bria-IMTu2122 proves effective in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Targeted treatment strategy
- Potential for personalized medicine
- Experienced management team
Weaknesses
- Limited clinical trial data
- High cash burn rate
- Reliance on a single lead product candidate
- Uncertainty regarding regulatory approval
Opportunities
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
- Advancements in companion diagnostics
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- NVS
- RO
Competitive Landscape
BriaCell faces competition from established pharmaceutical companies with broader pipelines and greater resources. Its advantage lies in its targeted immunotherapy approach, which may offer a more personalized treatment option.
Growth Trajectory and Initiatives
Historical Growth: BriaCell's growth is dependent on the success of its clinical trials and the development of its immunotherapy candidates. Historically, it has shown growth in research and development activities.
Future Projections: Future growth is contingent on the successful completion of clinical trials and potential regulatory approval of Bria-IMTu2122 and other immunotherapy candidates. Analyst projections vary widely based on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials of Bria-IMTu2122 in advanced breast cancer and exploring new immunotherapy combinations.
Summary
BriaCell Therapeutics is a clinical-stage biotechnology company with a focus on targeted cancer immunotherapies. Its future success depends heavily on the outcome of its clinical trials, particularly for its lead candidate Bria-IMTu2122. The company faces significant competition from larger pharmaceutical companies, and its high cash burn rate and reliance on a single product candidate are key risks to watch. Positive clinical results and strategic partnerships are critical for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share is estimated based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2025-04-25 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.